An inorganic Pyrophosphatase isolated from E. coli (patent on process) is the latest addition to Canvax© portfolio of enzymes to contribute to mRNA vaccines Manufacturing.
Canvax© announced the release of an improved Inorganic Pyrophosphatase (PPAse), a DNA replication enhancer with high purity (≥ 95%) and enhanced capacity of increasing RNA yield in In Vitro Transcription (IVT) reactions.
Increased need to powerful RNA reagents is essential nowadays due the present global focus on mRNA vaccines: “We’re glad to contribute with this new launch, significantly to supporting mRNA vaccines manufacturing, and we’re pleased that the research community has embraced our Pyrophosphatase and our RNA enzymes portfolio” said Jesus C. Morales, Business Development Manager from Canvax©.
Canvax© Pyrophosphatase has been proven stable under temperatures below 80º and endonucleases, exonucleases and RNAses free, ideal characteristics for its use in RNA IVT reactions to reduce the inhibitory effects of PPi, for mRNA-based vaccines manufacturing, for RNA labeling and for enhancement of DNA replication.
In addition, Canvax© offers different PPAse quality grades, from RUO to cGMP grade, adapting the production size and packing from lab scale to industry scale.
The full product description and ordering details can be found at its Product profile.
Since 2001, Canvax© has been an original European Manufacturer & Supplier of the Most Innovative Recombinant Proteins, Enzymes, Kits, Buffers and Reagents. Due a customizable and adaptable manufacturing structure with BULK capacity to manufacture from grams to Kilograms with the highest quality standards, Canvax© has become a leader within the Life Science industry in terms of product purity, production capabilities and service.
Actually, Canvax© offers a broad portfolio for IVT Enzymes includes, additionally to Inorganic Pyrophosphatase, a ready-to-use ultra-high yield enzymes such us T7 RNA Polymerase, SP6 RNA Polymerase, Vaccinia Capping, Poly A Polymerase, mRNA Cap 2-O-Methyltransferase or DNAse I.
From its 2,600m2 facilities in Valladolid (Spain), Canvax© manufactures its innovative products in a flexible quality standard that covers from Research to cGMP-grade. Its production facilities are designed and prepared to fulfill all type of requirements in terms of formats, timelines, quality and quantities, enabling a quick transition from lab-scale to commercial-scale mRNA manufacturing in just a few weeks.
Media Contact Information
Jesús Carlos Morales, MBA
Business Develepment Manager
Canvax Reagents S.L.U.
Tel: (+34) 983 548 563